NCT05178888View on ClinicalTrials.gov

Adagrasib in Combination With Palbociclib in Patients With Advanced Solid Tumors (KRYSTAL-16)

PHASE1CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

January 20, 2022

Primary Completion Date

June 15, 2023

Study Completion Date

December 30, 2024

Conditions
Advanced Solid Tumor
Interventions
DRUG

MRTX849

KRAS G12C inhibitor

DRUG

Palbociclib

CDK 4 and 6 inhibitor

Trial Locations (4)

32827

Local Institution - 804, Orlando

37203

Local Institution - 803, Nashville

77030

Local Institution - 802, Houston

78229

Local Institution - 801, San Antonio

Sponsors
All Listed Sponsors
lead

Mirati Therapeutics Inc.

INDUSTRY

NCT05178888 - Adagrasib in Combination With Palbociclib in Patients With Advanced Solid Tumors (KRYSTAL-16) | Biotech Hunter | Biotech Hunter